Stocks · News reference
Niki BioSolutions Announces Poster Presentation at CTAD 2026 Conference
Niki BioSolutions, Inc. announced that its subsidiary, DiamiR Biosciences Corp., will present a poster on APOE genotyping at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Niki BioSolutions Subsidiary DiamiR Biosciences Receives NYSDOH Approval for Expanded APOE Genotyping Specimen Types
Niki BioSolutions, Inc. announced that its subsidiary, DiamiR Biosciences Corp., received approval from the New York State Department of Health to expand the specimen types for its APOE Genotyping test.
New York State Department Of Health Provides Clinical Laboratory Evaluation Program Test Approval To Niki BioSolutions' DiamiR Biosciences Subsidiary For Its APOE Genotyping Test
Niki BioSolutions Subsidiary DiamiR Biosciences Signs APOE Genotyping Agreement with Charter Research
Niki BioSolutions, Inc. announced that its subsidiary, DiamiR Biosciences, has entered into an agreement to provide apolipoprotein E (APOE) genotyping services for Charter Research.
Niki BioSolutions' DiamiR Biosciences Subsidiary To Perform Apolipoprotein E Genotyping On Plasma Samples From Global Alzheimer’s Platform Foundation Bio-Hermes-002 Trial Group
Niki BioSolutions, Inc. (NASDAQ: NIKI) ("Niki" or the "Company"), a clinical-stage life sciences company focused on unmet medical needs and genomic and biomarker testing solutions, today announced that
8-K filing — Niki BioSolutions, Inc. (NIKI)
Filed: 2026-10-13 AccNo: 0001213900-26-109016 Size: 382 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits